Characterization of a new SARS-CoV-2 variant that emerged in Brazil

被引：54

作者：

Imai, Masaki ^{[1
]}

Halfmann, Peter J. ^{[2
]}

Yamayoshi, Seiya ^{[1
]}

Iwatsuki-Horimoto, Kiyoko ^{[1
]}

Chiba, Shiho ^{[2
]}

Watanabe, Tokiko ^{[1
,3
]}

Nakajima, Noriko ^{[4
]}

Ito, Mutsumi ^{[1
]}

Kuroda, Makoto ^{[2
]}

Kiso, Maki ^{[1
]}

Maemura, Tadashi ^{[1
,2
]}

Takahashi, Kenta ^{[4
]}

Loeber, Samantha ^{[5
]}

Hatta, Masato ^{[2
]}

Koga, Michiko ^{[6
,7
]}

Nagai, Hiroyuki ^{[7
]}

Yamamoto, Shinya ^{[6
,7
]}

Saito, Makoto ^{[6
,7
]}

Adachi, Eisuke ^{[7
]}

Akasaka, Osamu ^{[8
]}

Nakamura, Morio ^{[9
]}

Nakachi, Ichiro ^{[10
]}

Ogura, Takayuki ^{[11
]}

Baba, Rie ^{[10
]}

Fujita, Kensuke ^{[11
]}

Ochi, Junichi ^{[12
]}

Mitamura, Keiko ^{[13
]}

Kato, Hideaki ^{[14
,15
]}

Nakajima, Hideaki ^{[15
]}

Yagi, Kazuma ^{[16
]}

Hattori, Shin-Ichiro ^{[17
]}

Maeda, Kenji ^{[17
]}

Suzuki, Tetsuya ^{[18
]}

Miyazato, Yusuke ^{[18
]}

Valdez, Riccardo ^{[19
]}

Gherasim, Carmen ^{[19
]}

Furusawa, Yuri ^{[1
]}

Okuda, Moe ^{[1
]}

Ujie, Michiko ^{[1
]}

Lopes, Tiago J. S. ^{[1
,2
]}

Yasuhara, Atsuhiro ^{[1
]}

Ueki, Hiroshi ^{[1
]}

Sakai-Tagawa, Yuko ^{[1
]}

Eisfeld, Amie J. ^{[2
]}

Baczenas, John J. ^{[20
,21
]}

Baker, David A. ^{[20
]}

O'Connor, Shelby L. ^{[20
,21
]}

O'Connor, David H. ^{[20
,21
]}

Fukushi, Shuetsu ^{[22
]}

Fujimoto, Tsuguto ^{[23
]}

机构：

[1] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Virol, Tokyo 1088639, Japan

[2] Univ Wisconsin, Sch Vet Med, Influenza Res Inst, Dept Pathobiol Sci, Madison, WI 53711 USA

[3] Osaka Univ, Res Inst Microbial Dis, Dept Mol Virol, Osaka 5650871, Japan

[4] Natl Inst Infect Dis, Dept Pathol, Tokyo 1628640, Japan

[5] Univ Wisconsin, Sch Vet Med, Dept Surg Sci, Madison, WI 53706 USA

[6] Univ Tokyo, Adv Clin Res Ctr, Inst Med Sci, Div Infect Dis, Tokyo 1088639, Japan

[7] Univ Tokyo, IMSUT Hosp, Dept Infect Dis & Appl Immunol, Inst Med Sci, Tokyo 1088639, Japan

[8] Fujisawa City Hosp, Emergency Med Ctr, Fujisawa, Kanagawa 2518550, Japan

[9] Tokyo Saiseikai Cent Hosp, Dept Pulm Med, Tokyo 1080073, Japan

[10] Saiseikai Utsunomiya Hosp, Dept Internal Med, Pulm Div, Utsunomiya, Tochigi 3210974, Japan

[11] Saiseikai Utsunomiya Hosp, Dept Emergency & Intens Care, Utsunomiya, Tochigi 3210974, Japan

[12] Eiju Gen Hosp, Dept Resp Med, Tokyo 1108645, Japan

[13] Eiju Gen Hosp, Div Infect Control, Tokyo 1108645, Japan

[14] Yokohama City Univ Med, Infect Prevent & Control Dept, Yokohama, Kanagawa 2360004, Japan

[15] Yokohama City Univ, Dept Hematol & Clin Immunol, Sch Med, Yokohama, Kanagawa 2360004, Japan

[16] Keiyu Hosp, Dept Pulm Med, Yokohama, Kanagawa 2208521, Japan

[17] Natl Ctr Global Hlth & Med Res Inst, Dept Refractory Viral Infect, Tokyo 1628655, Japan

[18] Natl Ctr Global Hlth & Med Hosp, Dis Control & Prevent Ctr, Tokyo 1628655, Japan

[19] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA

[20] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53705 USA

[21] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA

[22] Natl Inst Infect Dis, Dept Virol 1, Tokyo 2080011, Japan

[23] Natl Inst Infect Dis, Ctr Emergency Preparedness & Response, Tokyo 1628640, Japan

[24] Natl Inst Infect Dis, Dept Vet Sci, Tokyo 1628640, Japan

[25] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA

[26] Keiyu Hosp, Dept Pediat, Yokohama, Kanagawa 2208521, Japan

[27] NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA

[28] Univ Tokyo, Inst Med Sci, Int Res Ctr Infect Dis, Dept Special Pathogens, Tokyo 1088639, Japan

来源：

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA | 2021年 / 118卷 / 27期

关键词：

SARS-CoV-2; P; 1; variant; Syrian hamsters; reinfection; convalescent; human plasma; RECEPTOR-BINDING DOMAIN; MUTATIONS;

D O I：

10.1073/pnas.2106535118

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays a key role in viral infectivity. It is also the major antigen stimulating the host's protective immune response, specifically, the production of neutralizing antibodies. Recently, a new variant of SARS-CoV-2 possessing multiple mutations in the S protein, designated P.1, emerged in Brazil. Here, we characterized a P.1 variant isolated in Japan by using Syrian hamsters, a well-established small animal model for the study of SARS-CoV-2 disease (COVID-19). In hamsters, the variant showed replicative abilities and pathogenicity similar to those of early and contemporary strains (i.e., SARS-CoV-2 bearing aspartic acid [D] or glycine [G] at position 614 of the S protein). Sera and/or plasma from convalescent patients and BNT162b2 messenger RNA vaccinees showed comparable neutralization titers across the P.1 variant, S-614D, and S-614G strains. In contrast, the S-614D and S-614G strains were less well recognized than the P.1 variant by serum from a P.1-infected patient. Prior infection with S-614D or S-614G strains efficiently prevented the replication of the P.1 variant in the lower respiratory tract of hamsters upon reinfection. In addition, passive transfer of neutralizing antibodies to hamsters infected with the P.1 variant or the S-614G strain led to reduced virus replication in the lower respiratory tract. However, the effect was less pronounced against the P.1 variant than the S-614G strain. These findings suggest that the P.1 variant may be somewhat antigenically different from the early and contemporary strains of SARS-CoV-2.

引用

页数：9

共 22 条

[21]

Weisblum Yiska, 2020, bioRxiv, DOI [10.7554/eLife.61312, 10.1101/2020.07.21.214759]

[22]

Zhou Peng, 2020, NATURE 0203, V579, P270, DOI DOI 10.1038/s41586-020-2012-7

← 1 2 3 →